BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18254752)

  • 1. Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes.
    Simitsopoulou M; Roilides E; Maloukou A; Gil-Lamaignere C; Walsh TJ
    Mycoses; 2008 Mar; 51(2):147-54. PubMed ID: 18254752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cunninghamella bertholletiae exhibits increased resistance to human neutrophils with or without antifungal agents as compared to Rhizopus spp.
    Simitsopoulou M; Georgiadou E; Walsh TJ; Roilides E
    Med Mycol; 2010 Aug; 48(5):720-4. PubMed ID: 20100138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of posaconazole in treatment of experimental disseminated zygomycosis.
    Dannaoui E; Meis JF; Loebenberg D; Verweij PE
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3647-50. PubMed ID: 14576138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility.
    Spreghini E; Orlando F; Giannini D; Barchiesi F
    J Antimicrob Chemother; 2010 Oct; 65(10):2158-63. PubMed ID: 20667887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes.
    Gil-Lamaignere C; Simitsopoulou M; Roilides E; Maloukou A; Winn RM; Walsh TJ
    J Infect Dis; 2005 Apr; 191(7):1180-7. PubMed ID: 15747255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B lipid complex exerts additive antifungal activity in combination with polymorphonuclear leucocytes against Scedosporium prolificans and Scedosporium apiospermum.
    Gil-Lamaignere C; Roilides E; Maloukou A; Georgopoulou I; Petrikkos G; Walsh TJ
    J Antimicrob Chemother; 2002 Dec; 50(6):1027-30. PubMed ID: 12461027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Posaconazole prophylaxis in experimental systemic zygomycosis.
    Barchiesi F; Spreghini E; Santinelli A; Fothergill AW; Pisa E; Giannini D; Rinaldi MG; Scalise G
    Antimicrob Agents Chemother; 2007 Jan; 51(1):73-7. PubMed ID: 17060525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amphotericin B formulations variably enhance antifungal activity of human neutrophils and monocytes against Fusarium solani: comparison with Aspergillus fumigatus.
    Dotis J; Simitsopoulou M; Dalakiouridou M; Konstantinou T; Panteliadis C; Walsh TJ; Roilides E
    J Antimicrob Chemother; 2008 Apr; 61(4):810-7. PubMed ID: 18272514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae.
    Chau AS; Chen G; McNicholas PM; Mann PA
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3917-9. PubMed ID: 16966400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes.
    Galgóczy L; Lukács G; Nyilasi I; Papp T; Vágvölgyi C
    Acta Biol Hung; 2010 Sep; 61(3):356-65. PubMed ID: 20724281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of media composition and in vitro activity of posaconazole, caspofungin and voriconazole against zygomycetes.
    Gil-Lamaignere C; Hess R; Salvenmoser S; Heyn K; Kappe R; Müller FM
    J Antimicrob Chemother; 2005 Jun; 55(6):1016-9. PubMed ID: 15883179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.
    Perkhofer S; Locher M; Cuenca-Estrella M; Rüchel R; Würzner R; Dierich MP; Lass-Flörl C
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2636-8. PubMed ID: 18458135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
    Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
    J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media.
    Vitale RG; Meis JF; Mouton JW; Verweij PE
    J Antimicrob Chemother; 2003 Jul; 52(1):65-70. PubMed ID: 12775672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro.
    Krishnan-Natesan S; Manavathu EK; Alangaden GJ; Chandrasekar PH
    Diagn Microbiol Infect Dis; 2009 Apr; 63(4):361-4. PubMed ID: 19302924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deoxycholate amphotericin B and amphotericin B lipid complex exert additive antifungal activity in combination with pulmonary alveolar macrophages against Fusarium solani.
    Roilides E; Lyman CA; Armstrong D; Stergiopoulou T; Petraitiene R; Walsh TJ
    Mycoses; 2006 Mar; 49(2):109-13. PubMed ID: 16466443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
    Perkhofer S; Lugger H; Dierich MP; Lass-Flörl C
    Antimicrob Agents Chemother; 2007 Feb; 51(2):791-3. PubMed ID: 17116665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro antifungal activity of amphotericin B lipid complex, amphotericin B and fluconazole.
    Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga M; Alonso R; del Valle O; Rodriguez V; Arévalo MP; Salgado J; Martin-Mazuelos E; Bornay-Llinares FJ; del Palacio A; Cuétara M; Gasser I; Hernández-Molina JM; Pemán J
    Chemotherapy; 2000; 46(4):235-44. PubMed ID: 10859429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis.
    Lamaris GA; Ben-Ami R; Lewis RE; Chamilos G; Samonis G; Kontoyiannis DP
    J Infect Dis; 2009 May; 199(9):1399-406. PubMed ID: 19358672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.